Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough exercises option for arthritis drug
As a result of the decision to exercise its rights to the compound, Schering-Plough says it will record an R&D charge of approximately $125 million in the third
As a result of the decision to exercise its rights to the compound, Schering-Plough says it will record an R&D charge of approximately $125 million in the third
The two designer cancer drugs appear to perform dramatically differently in a laboratory test comparing their ability to shut down a mutant, overactive growth signal in lung cancer
Conclusion of the transaction is now expected to occur in the third quarter of this year, subject to satisfaction of customary closing conditions, including regulatory approvals. Vicuron has
New studies in cell lines suggest that the combination, which targets a common gene pathway in colon cancer cells, could be more potent than either drug alone, and
The investigators from the University of Minnesota hope that by finding ways to increase the concentration of this regulator they may one day find a treatment for diabetes
The company is developing its “Tissue Repair Cells” for use in multiple medical indications, and has already received a phase I grant from the National Institute of Arthritis
Scientists have demonstrated that the loss of the p63 mouse gene, of which similar versions are present in many organisms, reduces the life expectancy of the rodents. Mice
The partnership now expects to commence a phase II clinical study with Moli1901 in dry eye syndrome. The companies said that they would share development and supply responsibilities
Under terms of the agreement, UCB and ImClone Systems will equally share the development costs for the drug, known as CDP-791, as well as worldwide profits derived from
Antibody optimization technologies assist drug companies in developing medicines with improved properties such as greater and longer lasting efficacy. Bioren has developed technologies called Walk-Through Mutagenesis (WTM) and